Tags : teriparatide

EMA’s CHMP Recommends the Approval of Two Biosimilar Referencing Lilly’s

Shots: The CHMP has adopted the positive opinion recommending the approval of Theramex’s  Livogiva (biosimilar, teriparatide) intended for the treatment of osteoporosis and will be available as a solution for injection (20 micrograms/80 microliters) The CHMP has also recommend marketing authorization to EuroGenerics’ Qutavina (biosimilar, teriparatide) to treat osteoporosis, also available as a solution for […]Read More

Alvogen Signs an Exclusive Commercialization Agreement with Three Pharma Companies

Shots: Alvogen collaborates with PharmBio, Kamada and Jamp to commercialize PF708 for the treatment of osteoporosis in South Korea, Israel and Canada respectively The focus of the collaboration is to build strong commercial networks in South Korea, Israel and Canada and to gain commercial expertise within the territories PF708 is a biosimilar referencing Eli Lilly’s […]Read More

Gedeon Richter Launches Terrosa (biosimilar, teriparatide) in Europe

Shots: Richter has launched Terrosa, a biosimilar to Eli Lilly’s Forsteo approved for osteoporosis in postmenopausal women and in men at high risk of fracture and treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture Richter launched Terrosa through its affiliates in Europe following the patent […]Read More

Pfenex and Alvogen Report EMA’s Acceptance of MAA for PF708

Shots: Pfenex and Alvogen announce that EMA has accepted MAA for its PF708, a biosimilar to Eli Lilly’s Forsteo which has generated $289M in EU & $1.6B globally in 2018 for the treatment of osteoporosis is expected to receive marketing authorization in all 28 states of EU, as well as in Iceland, Liechtenstein and Norway, […]Read More